Dacomitinib

(Vizimpro®)

Vizimpro®

Drug updated on 11/15/2023

Dosage FormTablet (oral; 15 mg, 30 mg, 45 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test

Product Monograph / Prescribing Information

Document TitleYearSource
Vizimpro (dacomitinib) Prescribing Information.2020Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib. 2023Translational cancer research
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis. 2023Frontiers in Pharmacology
Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis. 2023Chinese medical journal
Overall survival benefits of first-line treatments for Asian patients with advanced epidermal growth factor receptor-mutated NSCLC harboring exon 19 deletion: a systematic review and network meta-analysis.2022Cancers
Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis.2022JTO Clinical Research and Reports
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. 2021Future Oncology
Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer patients: a network meta-analysis. 2021Journal of Clinical Pharmacy and Therapeutics
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. 2021Critical Reviews in Oncology/Hematology
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. 2020BMJ
Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis.2020Lung Cancer Management
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer.2019NICE
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. 2019OncoTargets and Therapy
Final clinical guidance report: dacomitinib (Vizimpro) for non-small cell lung cancer. 2019CADTH

Clinical Practice Guidelines